Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

By Science Daily News –

CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy’s molecular target improved response. Source: Stanford Medicine.

Click Here to read the article

Related posts:

FDA sends warning to company for selling unapproved umbilical cord blood and umbilical cord products that may put patients at risk; continues to warn patients of the risk of unapproved stem cell therapy FDA Grants Regenerative Medicine Advanced Therapy Designation for AMT-130 Gene Therapy in Huntington Disease High-fiber diet cuts risk of rejected bone marrow and stem cell transplants, cancer research discovers